Cargando…
Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumors known, with an overall 5-year survival rate of less than 6% due to early local invasion and distant metastasis. Exploring suitable therapeutic targets associated with invasion and metastasis is required for improving the pr...
Autores principales: | Liu, Xinlu, Tan, Xiaodong, Liu, Peng, Wu, Yunhao, Qian, Songying, Zhang, Xiaobo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cognizant Communication Corporation
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844743/ https://www.ncbi.nlm.nih.gov/pubmed/29386088 http://dx.doi.org/10.3727/096504018X15166223632406 |
Ejemplares similares
-
The Design and Synthesis of N-Xanthone Benzenesulfonamides as Novel Phosphoglycerate Mutase 1 (PGAM1) Inhibitors
por: Wang, Penghui, et al.
Publicado: (2018) -
Identification of human phosphoglycerate mutase 1 (PGAM1) inhibitors using hybrid virtual screening approaches
por: Yousaf, Numan, et al.
Publicado: (2023) -
CBMS-02 Phosphoglycerate mutase 1 (PGAM1) controls DNA damage repair via regulation of WIP1 activity
por: Ohba, Shigeo, et al.
Publicado: (2020) -
Phosphoglycerate Mutase 1: Its Glycolytic and Non-Glycolytic Roles in Tumor Malignant Behaviors and Potential Therapeutic Significance
por: Li, Na, et al.
Publicado: (2020) -
Development of Anthraquinone Analogues as Phosphoglycerate Mutase 1 Inhibitors
por: Huang, Ke, et al.
Publicado: (2019)